Agentic Bioprocessing™
Begins Here.
Your process analytics measure the medium.
The biology that determines your outcome is happening inside the cell.
powered by InnoFluidics' proprietary microfluidic technology
Validated with
"InnoFluidics' technology has the potential to significantly advance our mission of delivering faster, better, and safer medicines to patients. Their full commitment to our joint project goals has been, and still is, exemplary."
Benoit Thienpont,
Senior Specialist - Microfluidic Technologies, GSK
The industry circles around the blind spot
The bioprocessing industry is caught in a self-reinforcing loop. Users demand more from existing sensors. Each incremental upgrade feels like progress. Add the promise of AI, and the conviction deepens: collect more data, apply more sophisticated models, and autonomous bioprocessing will emerge. It won't. Speed and sophistication cannot compensate for measuring the wrong thing.
We do not circle around the blind spot.
We build the perception layer that eliminates it.
up to
€500k
Cost per failed commercial batch
up to
15%
Industry-wide batch failure rate
14 days
CHO fed-batch duration with zero intracellular visibility
It starts with physics
The prevailing assumption is that Agentic Bioprocessing™ will arrive top-down: an AI company will collect massive data, train a large model, and intelligence will emerge. There is a ceiling: no algorithm can interpret biology it cannot observe. InnoFluidics builds the entire pipeline from the bottom up. From the measurement physics to the fleet knowledge repository.
Others see it coming someday. We are building it now.
The question: who joins us at the beginning?
up to
300%
Increase in efficiency for process optimization phase
up to
40%
Reduction in total upstream process development timeline
over
€1M
Direct annual saving for process development
Immediate value: 5 decisions you make better on Day 1
Decision
What you see today
What you miss
What InnoFluidics adds
Clone selection
Which clone do I advance?
VCD, viability, titer at Day 14 endpoint. All clones look similar at Day 7.
Intracellular stress that has not yet manifested in viability or titer.
Compartment-level status per clone, daily. Kill underperformers at Day 7 instead of Day 14. Save 3–4 weeks per screening round.
Media/feed optimisation
Which formulation is best?
Metabolite profiles and titer after 14-day DoE runs. Output metrics only.
How each formulation affects the cell at the biophysical level. Which conditions produce the most homogeneous, stable population.
Population composition per condition. Identify the optimal formulation 1–2 DoE rounds sooner.
Metabolic shift detection
Is my culture drifting?
Lactate accumulation in the medium (Raman, FLEX2). By the time you see it, the intracellular shift happened 24–48 hours earlier.
The glycolytic transition inside the cell before it reflects in the medium.
Metabolic compartment status flags the shift at the source. Intervene 24–48 hours earlier: adjust feed timing, temperature, pH.
Harvest timing
When do I stop?
Viability decline below 80% + titer plateau. Lagging indicators. By the time viability drops, product quality has already degraded.
Onset of apoptotic sub-populations before viability drops.
Population decomposition detects stress onset. Harvest at peak product quality, not peak titer.
Scale-up comparability
Is my 2L the same as my 2000L?
VCD/viability curves and metabolite profiles overlaid across scales. Indirect, low-resolution.
Whether the cells themselves are biophysically equivalent across scales, rather than just their medium footprint.
Physics-grounded biophysical fingerprinting. If the intracellular profiles match, the biology matches regardless of physical differences in mixing or gas transfer.
The Cellular Data Cosmos
This is a simulated CHO fed-batch culture over 14 days. Each point is a single cell. Colour represents intracellular metabolic state, which is measured directly by the Dispersion Interaction Tensor. Watch the population evolve from exponential growth through lactate switching to stationary phase. Click any cell to inspect its full biophysical profile. No other process analytical tool generates this view.
"The industry has spent decades optimising based on indirect measurements. We're building the foundation for direct biological understanding."
Sertan Sukas,
Founder & CEO, InnoFluidics
Ready to Transform Your Bioprocess?
Contact us today. Our team will respond quickly.
Follow us on LinkedIn:
InnoFluidics:
InnoFluidics Diagnostics: